ERBB2 and ovarian carcinoma: While there have been a number of disease context‐specific practice‐changing discoveries, such as HER2‐targeted therapy in HER2 amplified breast and gastroesophageal cancers, or poly(ADP‐ribose) polymerase (PARP) inhibition in ovarian cancers with homologous DNA repair deficiency, there still appear to be a range of responses to appropriately selected therapy and the eventual development of drug resistance.